The biologic treatment missed the primary endpoint, but did show some improvements in those given the drug and may be better ...

Mesoblast has received FDA approval for Ryoncil, becoming the first and only cell therapy of its kind to be available in the ...

The anti-TL1A antibody allowed significantly more inflammatory bowel disease (IBD) patients to go into remission than those ...

The Swedish pharma company Orexo and biotech firm Abera Bioscience announced today that they have joined forces to develop ...

The merger of Nvelop Therapeutics and Chroma Medicine brings together a combination of epigenetic editing and in vivo ...

Enrollment in the Phase 1/2 ASTRA study is set to start in the first half of 2025. The study will observe the safety and ...